Canine Dilated Cardiomyopathy Drugs Market

Canine Dilated Cardiomyopathy Drugs Market Overview

Global Canine Dilated Cardiomyopathy Market demand is anticipated to be valued at US$ 3.4 Billion in 2022, forecast to grow at a CAGR of 4.93% to be valued at US$ 5.5 Billion from 2022 to 2032. The growth of the Canine Dilated Cardiomyopathy Market is attributed to its global utilization across the Healthcare industry.

Canine dilated cardiomyopathy drugs are used to treat heart muscle diseases, which causes the heart to weaken and enlarge. This results in weaken contraction and poor pumping ability of the heart. The canine dilated cardiomyopathy is prevalent in certain breeds of dog and is observed to be rare in crossbreed dogs.

Canine dilated cardiomyopathy drugs are directed at enhancing systolic (pump) function of the heart, dilating the peripheral blood vessels to lower ventricular workload, controlling heart rate and cardiac arrhythmias. Canine dilated cardiomyopathy drugs treatment goals are achieved by the administration of cardiac medication which may be delivered through injections in an emergency situation or orally in stable animals.

Asia Pacific is considered to be a dominant region for the Canine Dilated Cardiomyopathy Market during the forecast period, owing to the increasing pet culture in the region.

The major factor that is expected to propel the growth of the Canine Dilated Cardiomyopathy Market during the forecast period includes rising health benefits for pet animals.

The factor that is expected to hinder the growth of the Canine Dilated Cardiomyopathy Market during the forecast period includes the high cost and side effects associated with products and treatments

Which are Some Prominent Drivers Spearheading Canine Dilated Cardiomyopathy Market Growth?

The major factor that is expected to accelerate the growth of the Canine Dilated Cardiomyopathy Market during the forecast period includes potential growth of the pet industry.

In addition, dogs are estimated to account for the largest share in the pet industry due to rising health benefits for pet animals, which in turn is expected to fuel the growth of the Canine Dilated Cardiomyopathy Market during the forecast period.

Furthermore, increasing prevalence of cardiac diseases, technological advancement in the diagnostic treatments, and more life expectancy of animals are some other factors that are expected to propel the growth of canine dilated cardiomyopathy drugs market during the forecast period.

What are the Challenges Faced by the Canine Dilated Cardiomyopathy Industry?

The major factor that is expected to hamper the growth of the Canine Dilated Cardiomyopathy Market during the forecast period includes the high cost and side effects associated with products and treatments.

Additionally, lack of veterinary infrastructure, as well as poor transportation links in some regions are some other factors that are expected to hinder the market growth.

How is Asia Pacific region emerging as an Opportunistic Canine Dilated Cardiomyopathy Market?

Asia Pacific is the largest market for Canine Dilated Cardiomyopathy, owing to the high prevalence of disease conditions such as cancer and cardiovascular diseases in the region. Moreover, India and China are promising markets for the growth of dilated cardiomyopathy market due to increasing incidences of Cancer among patients.

In addition, increase in various therapy devices including implantable cardioverter-defibrillators (ICDs), biventricular pacemakers and heart pumps in the Asia Pacific region is expected to fuel the growth of the Canine Dilated Cardiomyopathy Market in the region. The Asia Pacific canine dilated cardiomyopathy market is expected to expand at a 3% CAGR during the forecast period.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is North America Contributing to Growth of the Canine Dilated Cardiomyopathy Market?

According to Future Market Insights, North America is anticipated to witness growth at a lucrative rate over the forecast period, owing to the increasing pet culture in the region. This factor is expected to fuel the growth of the Canine Dilated Cardiomyopathy Market in the region.

Further, growing incidences of Cancer in the US is expected to accelerate the market growth in the region in the forthcoming years.

Market Competition

Some of the key participants present in the global Canine Dilated Cardiomyopathy Market include C.H. Boehringer Sohn AG & Co., KG, Merck & Co., Dechra Pharmaceuticals PLC, Zoetis Inc., Bayer AG, Orion, Elanco, and SAVA Vet, among others.

Attributed to the presence of such high number of participants, the market is highly competitive. While global players such as C.H. Boehringer Sohn AG & Co., and KG, Merck & Co. account for a considerable market size, several regional level players are also operating across key growth regions, particularly in the Asia Pacific.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Report Scope

Key Segments Profiled in the Canine Dilated Cardiomyopathy Drugs Industry Survey

Drug Class:

• Canine Dilated Cardiomyopathy ACE Inhibitors
• Canine Dilated Cardiomyopathy Vasodilators
• Canine Dilated Cardiomyopathy Diuretics
• Canine Dilated Cardiomyopathy Angiotensin II Receptor Blockers (ARB)
• Canine Dilated Cardiomyopathy Cardiac Glycosides
• Anti-arrhythmic Canine Dilated Cardiomyopathy Drugs
• Pimobenden Canine Dilated Cardiomyopathy Drugs

Route of Administration:

• Oral Canine Dilated Cardiomyopathy Drugs
• Injectable Canine Dilated Cardiomyopathy Drugs

Distribution Channel:

• Institutional Sales
  • Veterinary Hospitals
  • Veterinary Clinics
• Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa